Featured Press Releases

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • 18 Aug 2025

Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on developing and...

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

ELIQUENT Life Sciences Acquires Truliant Consulting, Expanding Pharmacovigilance Platform

ELIQUENT Life Sciences Acquires Truliant Consulting, Expanding Pharmacovigilance Platform

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

  • Cellenkos, Inc.
  • 27 Apr 2026
Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

  • Ascletis Pharma Inc.
  • 27 Apr 2026
OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

  • OrthoTrophix, Inc.
  • 26 Apr 2026
“O’Shaughnessy Ventures supports scientist uncovering biology’s hidden communication system

“O’Shaughnessy Ventures supports scientist uncovering biology’s hidden communication system

  • O'Shaughnessy Ventures
  • 24 Apr 2026
Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

  • Bristol Myers Squibb
  • 24 Apr 2026
CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

  • Neurocrine Biosciences, Inc.
  • 22 Apr 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.